Article citationsMore>>
Chan, D.C., Watts, G.F., Barrett, P.H., Martins, I.J., James, A.P., Mamo, J.C., Mori, T.A. and Redgrave, T.G. (2002) Effect of Atorvastatin on Chylomicron Remnant Metabolism in Visceral Obesity: A Study Employing a New Stable Isotope Breath Test. Journal of Lipid Research, 43, 706-712.
has been cited by the following article:
-
TITLE:
Induction of NAFLD with Increased Risk of Obesity and Chronic Diseases in Developed Countries
AUTHORS:
Ian James Martins
KEYWORDS:
Global, Induction, Obesity, Nutrition, Xenobiotic
JOURNAL NAME:
Open Journal of Endocrine and Metabolic Diseases,
Vol.4 No.4,
April
29,
2014
ABSTRACT: The susceptibility of individuals to obesity has been reported in many developed countries with predisposition of humans to obesity associated with high calorie diets and unhealthy lifestyles. Obesity may closely be involved in cell suicide in various organ diseases with the importance of accelerated aging that requires early intervention with drug therapy to prevent diseases such as non alcoholic fatty liver disease (NAFLD) that has increased in children and reached to approx. 40% of the global population. Obesity is induced by various diets and lifestyle factors such as stress, anxiety and depression which are important to consider with the global increase in obesity and are possibly linked to the rise in individuals with brain disorders that involve neurodegeneration. Xenobiotics such as the endocrine disruptor chemicals that have increased in the environment in various developed countries lead to various chronic endocrine diseases as populations divert towards unhealthy diets and lifestyles with induction of NAFLD and obesity. The amount and nature of food intake that improves and increases liver lipid and xenobiotic metabolism in obese individuals have become important to decrease the risk for increased adiposity in man. High fibre or protein diets that contain leucine may improve liver glucose, lipid and xenobiotic metabolism and require further investigation with xenobiotics such as endocrine disruptors involved in appetite dysregulation and metabolic disorders in developed countries. The use of anti-obese drugs that reduce food intake and improve hypercholesterolemia and cardiovascular disease has been assessed in obesity with drug therapy closely involved either in the prevention or induction of NAFLD and obesity in man.